Reflux testing and treatment
Radiofrequency ablation is a treatment for patients diagnosed with Barrett’s esophagus.
Barrett’s esophagus is the primary risk factor for esophageal adenocarcinoma (EAC), a form of esophageal cancer. Developing Barrett’s increases your chances of developing EAC by 40 to 125 times.1 Patients with confirmed low-grade dysplasia and other risk factors face a risk of disease progression.2,3
Radiofrequency ablation (RFA) is a treatment for patients diagnosed with Barrett’s esophagus. Multiple studies demonstrate the effectiveness of RFA in treating Barrett’s esophagus.4-8 Additionally, clinical guidelines from the three gastrointestinal (GI) societies in the United States recommend the option of patients with dysplasia endoscopic eradication therapy such as RFA.9,10
Undergoing treatment with the radiofrequency ablation can eradicate Barrett’s esophagus and reduce the relative risk of disease progression from low-grade dysplasia to high-grade dysplasia or EAC by up to 94%.*,2
Radiofrequency ablation (RFA) uses heat to remove precancerous tissue damaged by Barrett’s esophagus. The Barrx™ radiofrequency ablation system technology is designed for the removal of tissue affected by Barrett’s, while preserving the underlying healthy tissue.11
Information and resources on this site should not be used as a substitute for medical advice from your doctor. Always discuss diagnosis and treatment information including risks with your doctor. Keep in mind that all treatment and outcome results are specific to the individual patient. Results may vary.
94% is the calculated relative risk reduction [ (26-1.5) /26 ] = 25/26 X 100. From [25.0%(1.5% for ablation versus 26.5% for control); 95%CL, 14.1%-35.9%; P< 0.001].
Shaheen NJ, Ransohoff D. Gastroesophageal Reflux, Barrett Esophagus, and Esophageal Cancer. JAMA. April 2002;287(15)1972-1981.
Phoa KN, van Vilsteren FG, Pouw RE, Weusten BL, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014 Mar 26;311(12):1209-17.
Spechler S. et al. Barrett’s Esophagus. N Engl J Med 2014; 371:836-45.
Phoa KN, van Vilsteren FG, Pouw RE, et al. Radiofrequency Ablation in Barrett’s Esophagus with Confirmed Low-Grade Dysplasia: Interim Results of a European Multicenter Randomized Controlled Trial (SURF). Gastroenterology 2013;144:S-187. Page S-187, Col 1.
Orman ES, Li N, Shaheen NJ. Efficacy and durability of radiofrequency ablation for Barrett's esophagus: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2013;11:1245-55.
Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett’s esophagus with dysplasia. N Engl J Med 2009;360:2277-88. Page 2277, Page 2283, Figure 3.
van Vilsteren FG, Pouw RE, Seewald S, et al. Stepwise radical endoscopic resection versus radiofrequency ablation for Barrett’s oesophagus with high-grade dysplasia or early cancer: a multicenter randomized trial. Gut 2011;60:765-73. Page 765, Col 1 and Page 769, Table 2.
Phoa KN, Pouw RE, van Vilsteren FG, et al. Remission of Barrett’s Esophagus with Early Neoplasia 5 Years after Radiofrequency Ablation with Endoscopic Resection: A Netherlands Cohort Study.
Shaheen NJ, Falk GW, Iyer PG, Gerson LB. ACG Clinical Guideline: Diagnosis and Management of Barrett’s Esophagus. The American Journal Of Gastroenterology. 2016;111(1):30-50.
Wani S, Qumseya B, Sultan S, et al. Endoscopic eradication therapy for patients with Barrett’s esophagus-associated dysplasia and intramucosal cancer. Gastrointestinal Endoscopy. 2018;87(4):907-931.
Fleischer DE, Overholt BF, Sharma VK, et al. Endoscopic ablation of Barrett’s esophagus: a multicenter study with 2.5-year follow-up. Gastrointest Endosc. 2008;68:867-876.